Community Level Interventions for Pre-eclampsia (CLIP)
This project is being undertaken to test the hypothesis that implementing a community based package of care for women with hypertensive disorders of pregnancy will result in overall improvement in maternal and neonatal outcomes. This is based on the premise that there are three main modifiable reasons why women (and their fetuses/newborns) die due to pregnancy complications: 1) delays by the woman herself in recognizing the seriousness of her condition; 2) delays in her being assessed and then transported to a center capable of providing effective and life-saving interventions; and 3) delays in the health facility in providing those interventions. The treatments for pre-eclampsia that are poorly accessed in LMIC are 1) magnesium sulfate (MgSO4) for prevention and treatment of the grand mal seizures of eclampsia; 2) oral antihypertensive medication to lower maternal BP to reduce the risk of stroke.
The CLIP pilot and definitive cRCT will investigate whether the community level intervention including implementation of the CLIP package (oral antihypertensive therapy when indicated, intramuscular (i.m.) MgSO4 when indicated; and appropriate referral to an CEmOC facility when indicated) of care will reduce the incidence of all-cause maternal morbidity and mortality.
Hypertension, Pregnancy Induced
Behavioral: Community Engagement
Device: PIERS on the Move mHealth decision aid
Drug: Magnesium Sulfate
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
|Official Title:||The CLIP (Community Level Interventions for Pre-eclampsia) Cluster Randomized Controlled Trial|
- Maternal or Perinatal death or morbidity [ Time Frame: within 42 days of pregnancy ] [ Designated as safety issue: No ]
Combined outcome including any one of the following:
- Maternal death (defined as the number of deaths during pregnancy or within 42 days of pregnancy (or last contact day if contact not maintained to 42 days) / 1,000 identified pregnancies), termed Maternal Death Rate.
- Maternal morbidity (defined as the number of women with one or more life-threatening complications of pregnancy (i.e. eclampsia, major PPH requiring surgical intervention, obstetric sepsis, stroke, etc.) during pregnancy or within 42 days of pregnancy or last contact day if contact not maintained to 42 days) / 1,000 identified pregnancies
- Perinatal death (defined as stillbirth [≥20+0 and/or ≥500g], early neonatal mortality [d 0-7 of postnatal life] and late neonatal mortality [d 8-28 of postnatal life] / 1,000 identified pregnancies)
- Neonatal morbidity (defined as non-lethal events of seizure and coma30 during d 0-28 of postnatal life / 1,000 identified pregnancies)
- Birth preparedness and complication readiness [ Time Frame: from 20 weeks gestation to delivery ] [ Designated as safety issue: No ]as measured by any three of the following: (1) arranged for transport; (2) obtained prior permission for transport should emergency arise; (3) saved money for obstetric care; (4) identified skilled birth attendant; (5) identified facility for delivery. This will evaluate the success of community engagement.
- Facility births [ Time Frame: from 20 weeks gestation to delivery ] [ Designated as safety issue: No ]number of women presenting for delivery in a CEmONC facility in control vs intervention clusters
- Pre-eclampsia knowledge [ Time Frame: from 20 weeks gestation to time of delivery ] [ Designated as safety issue: No ]
- Post-trial seizures [ Time Frame: within 42 days of pregnancy ] [ Designated as safety issue: No ]Assessment of post-trial start eclamptic seizures in control vs intervention clusters to assess effectiveness of community dosing of magnesium sulfate
- Cost-effectiveness [ Time Frame: within 42 days of pregnancy ] [ Designated as safety issue: No ]Of the CLIP package against QALYs
- Adverse effects [ Time Frame: within 42 days of pregnancy ] [ Designated as safety issue: Yes ]Adverse effects of magnesium include injection site hematoma or infection, and respiratory depression
- Functional disability [ Time Frame: within 6 months of delivery ] [ Designated as safety issue: No ]Index measurement of functional ability, including ability to care for baby, do household chores and return to work within 6 months of delivery measured at two to four week intervals postpartum.
|Study Start Date:||September 2013|
|Estimated Study Completion Date:||December 2017|
|Estimated Primary Completion Date:||December 2017 (Final data collection date for primary outcome measure)|
The CLIP intervention consists of (i) community engagement including community leaders, the women of the communities themselves, and their mothers, husbands, and mothers-in-law, regarding pre-eclampsia, its origins, symptoms, signs, and potential consequences, pre-permissions for maternal transport, and fundraising activities around transport and treatment costs; (ii) provision of HDP oriented antenatal care through CLIP visits and use of CLIP "PIERS on the Move" mHealth tool (for risk stratification), and (iii) use of the CLIP package for women with a CLIP 'trigger' (i.e., oral antihypertensive therapy (methyldopa) when indicated, intramuscular (i.m.) magnesium sulfate when indicated; and appropriate referral to an CEmOC facility when indicated)
Behavioral: Community Engagement
The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,Device: PIERS on the Move mHealth decision aid
This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (>160mmHg systolic) or proteinuria (>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.
Other Name: CLIP mHealth toolDrug: Magnesium Sulfate
Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.
Other Name: MgSO4Drug: Methyldopa
Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
Other Name: Aldomet
No Intervention: Control
Current standard of antenatal care
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01911494
|Contact: Beth Payneemail@example.com|
|Contact: Sharla Drebitfirstname.lastname@example.org|
|Jawaharlal Nehru Medical College, Karnataka Lingayat Education University||Recruiting|
|Belgaum, Karnataka, India|
|Contact: Umesh Charantimath|
|Principal Investigator: Mrutunjaya Bellad|
|Sub-Investigator: Shivaprasad Goudar|
|Sub-Investigator: Ashalata Mallapur|
|Centro de Investigacaoem Saude de Manhica (CISM)||Not yet recruiting|
|Contact: Esperanca Sevene|
|Contact: Eusebio Macete|
|Principal Investigator: Esperanca Sevene|
|Sub-Investigator: Khatia Munguambe|
|Sub-Investigator: Eusebio Macete|
|Centre for Research in Reproductive Health, Olabisi Onabanjo University||Recruiting|
|Sagamu, Ogun State, Nigeria|
|Principal Investigator: Femi Oladapo|
|Sub-Investigator: Olukayode A Dada|
|Sub-Investigator: Olalekan Adetoro|
|Aga Khan University||Recruiting|
|Karachi, Sindh, Pakistan|
|Principal Investigator: Rahat Qureshi|
|Sub-Investigator: Zulfiqar Bhutta|
|Principal Investigator:||Peter von Dadelszen, MBChB, DPhil||University of British Columbia|